is a drug prescribed for the treatment of cardiac arrhythmias. Multaq is manufactured by the Paris based pharmaceutical company Sanofi-Aventis. The U.S. Food and Drug Administration approved Multaq in July of 2009. Multaq helps maintain normal heart rhythms in patients, who have a history heart rhythm disorders, such as cardiac arrhythmia, atrial fibrillation and atrial flutter. Multaq contains Dronedarone as main active ingredient. Clinical trials showed that Multaq reduced cardiovascular hospitalization or death by 24 percent. It has shown positive results, especially in patients having history of atrial fibrillation. Heart rhythm disorders such as a-fib and atrial flutter could prevent pumping of blood out of the heart. The approval in July of 2009 did come with a request for a box warning asking physicians to not use this drug in severe heart failure patients.

Previous ArticleMetal-on-Metal Hip Implants Not Worth the Safety Risk Next ArticleRiata ICD Leads
Verdicts and Settlements
Newsletter
Contact Us

Subscribe Now!

[contact-form-7 404 "Not Found"]

Follow Us!

Unsafe Drugs has numerous resources on drug side effects,nutritional supplements, vitamins, and health products.

Site best viewed in Google Chrome, Firefox, Opera, Safari, IE browsers